Loading...
Loading...
Browse all stories on DeepNewz
VisitGenentech, Roche Unit, Reintroduces Susvimo Eye Implant After Recall
Jul 8, 2024, 07:24 PM
Genentech, a unit of Roche Group, has announced the reintroduction of its eye implant, Susvimo, in the United States. The implant is designed for people with wet age-related macular degeneration (AMD), a blinding eye disease. The re-launch follows the end of a voluntary recall that took place two years ago. Susvimo, which was recalled, is a refillable implant, and it will be available to patients in the coming weeks. The announcement was made on Monday.
View original story
Markets
No • 50%
Yes • 50%
Genentech press releases and FDA adverse event reporting system
Yes • 50%
No • 50%
FDA official announcements and Genentech press releases
No • 50%
Yes • 50%
Genentech quarterly financial reports
Less than 10% • 25%
More than 30% • 25%
20% to 30% • 25%
10% to 20% • 25%
Market research reports and Genentech financial disclosures
Other • 25%
Adverse events • 25%
Lack of efficacy • 25%
Cost • 25%
Genentech patient surveys and medical reports
South • 25%
West • 25%
Northeast • 25%
Midwest • 25%
Genentech regional sales data and market analysis reports